Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Zbynek Bortlicek"'
Autor:
Radek Lakomy, Alexandr Poprach, Zbynek Bortlicek, Bohuslav Melichar, Renata Chloupkova, Rostislav Vyzula, Milada Zemanova, Katerina Kopeckova, Marek Svoboda, Ondrej Slaby, Igor Kiss, Hana Studentova, Jaroslav Juracek, Ondrej Fiala, Jindrich Kopecky, Jindrich Finek, Ladislav Dusek, Karel Hejduk, Tomas Buchler
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background It is well known that patient characteristics and survival outcomes in randomized trials may not necessarily be similar to those in real-life clinical practice. The aim of the present study was to analyse second line treatment str
Externí odkaz:
https://doaj.org/article/0a8555e1bc4d4de2ae22bfbdd71ada34
Autor:
Jana Hornova, Zbynek Bortlicek, Petra Majkova, Jitka Abrahamova, Drahomira Kordikova, Zuzana Donatova, Martin Kupec, Ludmila Boublikova, Josef Dvorak, Radek Zapletal, Tomas Buchler
Publikováno v:
Biomedical Papers, Vol 161, Iss 2, Pp 217-222 (2017)
Background: Although locally advanced breast cancer (LABC) is more common in the elderly population, there is little data on the clinical characteristics and survival of these patients. The aim of the present study was to compare different factors af
Externí odkaz:
https://doaj.org/article/89f4e8375ef2410b8294d580ae7a7369
Autor:
Zdenek Rehak, Jiri Vasina, Petr Nemec, Zdenek Fojtik, Renata Koukalova, Zbynek Bortlicek, Dorota Rehakova, Jan Adam, Alena Vavrusova, Zdenek Adam
Publikováno v:
Biomedical Papers, Vol 159, Iss 4, Pp 629-636 (2015)
Aim: Polymyalgia rheumatica (PMR) is a disease presenting with pain and stiffness, mainly in shoulders, hip joints and neck. Laboratory markers of inflammation may bolster diagnosis. PMR afflicts patients over 50 years old, predominantly women, and m
Externí odkaz:
https://doaj.org/article/c523cb5caa734d29b127f38e9639a627
Autor:
Andrea Janíková, Michaela Hamouzova, Marek Trneny, Samuel Vokurka, Jiri Mayer, Jan Pirnos, Heidi Mocikova, Natasa Kopalova, Vít Procházka, Zbynek Bortlicek, Robert Pytlik, Vit Campr, Juraj Duras, Katerina Benesova, David Belada
Publikováno v:
Annals of Hematology. 97:669-678
The aim of this study is to assess the incidence, risk factors, and outcome of biopsy-proven transformation in follicular lymphoma (FL) patients in the rituximab era. Transformation was analyzed in 1233 patients with initially diagnosed FL grades 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b12a5613f1ff3caec3f3d54bbf99882
https://doi.org/10.1007/s00277-017-3218-0
https://doi.org/10.1007/s00277-017-3218-0
Autor:
Ondrej Slaby, Katerina Kopeckova, Tomas Buchler, Igor Kiss, Renata Chloupková, Radek Lakomy, Ondrej Fiala, Alexandr Poprach, Bohuslav Melichar, Milada Zemanova, Rostislav Vyzula, Jindrich Finek, Marek Svoboda, Ladislav Dušek, Hana Študentová, Jana Hornova, Jindrich Kopecky, Zbynek Bortlicek
Publikováno v:
Clinical Genitourinary Cancer. 15:e1047-e1053
Background Although targeted therapies with inhibitors of the vascular endothelial growth factor (VEGF) are the mainstay of treatment for metastatic renal cell carcinoma, there are limited data on the outcome of patients with long-term response to th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd25c5b0f7e4c87b78f93ec44ace9f11
https://doi.org/10.1016/j.clgc.2017.06.006
https://doi.org/10.1016/j.clgc.2017.06.006
Autor:
Drahomira Kordikova, Petra Májková, Ludmila Boublikova, Tomas Buchler, Zbynek Bortlicek, Josef Dvorak, Jana Hornova, Jitka Abrahámová, Zuzana Donátová, Radek Zapletal, Martin Kupec
Publikováno v:
Biomedical Papers, Vol 161, Iss 2, Pp 217-222 (2017)
Background: Although locally advanced breast cancer (LABC) is more common in the elderly population, there is little data on the clinical characteristics and survival of these patients. The aim of the present study was to compare different factors af
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::116ce087ee3b27d079d73d4f15b416e2
https://doi.org/10.5507/bp.2017.011
https://doi.org/10.5507/bp.2017.011
Autor:
Zdenek Fojtik, Zbynek Bortlicek, Andrea Šprláková-Puková, Renata Koukalová, Zdenek Rehak, Marek Joukal, Jana Eremiášová, Jiri Vasina, Petr Nemec, Tomas Kazda
Publikováno v:
Radiology and Oncology, Vol 51, Iss 1, Pp 8-14 (2017)
Background The role of 18F-fluorodeoxyglucose positron emission computed tomography (18F-FDG PET/CT) is increasing in the diagnosis of polymyalgia rheumatica (PMR), one of the most common inflammatory rheumatic diseases. In addition to other location
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dbbd9a7a879347f848222fdedbf255b
https://doi.org/10.1515/raon-2017-0001
https://doi.org/10.1515/raon-2017-0001
Autor:
Jozef Michalka, Vít Procházka, Zbynek Bortlicek, Natasa Kopalova, Andrea Janíková, Jan Pirnos, David Belada, Marek Trneny, Heidi Mocikova, Pavel Klener, Jitka Hamouzova, Katerina Benesova, Renata Chloupková, Vit Campr, Robert Pytlik, Juraj Duras
Publikováno v:
Annals of hematology. 99(7)
Relapsing diffuse large B cell lymphomas (rDLBCL) represent a heterogeneous disease. This heterogeneity should be recognized and reflected, because it can deform the interpretation of clinical trial results. DLBCL patients with the first relapse and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51115a7552ac84a09feb76a04026c44f
https://pubmed.ncbi.nlm.nih.gov/32506244
https://pubmed.ncbi.nlm.nih.gov/32506244
Autor:
Jana Prausová, Igor Kiss, Zdenek Linke, Jiri Tomasek, Petra Pokorná, Tomas Buchler, Karel Hejduk, Bohuslav Melichar, Zbynek Bortlicek, Lubos Petruzelka, Renata Chloupková, Katerina Kopeckova
Publikováno v:
Targeted Oncology. 12:89-95
To describe the use of regorafenib for the treatment of metastatic colorectal cancer (mCRC) in clinical practice in the Czech Republic, and to describe the clinical outcomes of patients in terms of safety and survival.The data of patients treated wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55c38fa0cefbbc415bb13d16bff4655d
https://doi.org/10.1007/s11523-016-0458-1
https://doi.org/10.1007/s11523-016-0458-1
Autor:
Marian Hajduch, Jitka Mlčochová, Zbynek Bortlicek, Ondrej Slaby, Tomas Buchler, Petra Vychytilova-Faltejskova, Ales Ryska, Jiri Drabek, Igor Kiss, Marek Svoboda, Stanislav Batko, Alexandr Poprach
Publikováno v:
Anticancer Research. 36:4955-4960
Background: In metastatic colorectal cancer (mCRC), panitumumab is generally considered to be ineffective after the progression on cetuximab therapy. However, few studies have demonstrated that a small subset of mCRC patients may benefit from panitum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d86d3d4dc21af2a042cd32e5ee39132f
https://doi.org/10.21873/anticanres.11063
https://doi.org/10.21873/anticanres.11063